Lead Product(s) : Glofitamab,Lenalidomide,Poseltinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Updated results from the phase II NP30179 study will show a fixed course of glofitamab monotherapy can deliver durable complete responses in people with heavily pre-treated aggressive lymphomas.
Product Name : Columvi
Product Type : Antibody
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : Glofitamab,Lenalidomide,Poseltinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable